07:24 AM EST, 03/03/2025 (MT Newswires) -- TG Therapeutics ( TGTX ) reported a Q4 net income Monday of $0.15 per diluted share, swinging from loss of $0.10 a year earlier.

Analysts polled by FactSet expected earnings of $0.16.

Revenue for the quarter ended Dec. 31 was $108.2 million, up from $44 million a year earlier.

Analysts surveyed by FactSet expected $100.7 million.

The company said it expects full-year 2025 revenue of around $540 million. Analysts polled by FactSet expect $534.4 million.

As of Dec. 31, the company said it had $311 million in cash, cash equivalents and investment securities, which combined with the expected revenue from Briumvi, will be "sufficient" to fund the company's business based on its current operating plan.